EFTA02117655

To: Richard Kahn From: Sent Fri 1/10/2014 8:16:10 PM Subject: Re: Jeffrey Epstein-Invoice? and i have even more than that...i'm sure he thinks I am a pest...hopefully he thinks I'm thorough! ;) On Jan 10, 2014, at 3:05 PM, Richard Kahn wrote: that page is called thorough there is no better than you thanks for the update Richard Kahn HBRK Associates Inc. New York, New York 10022 tel fa On Jan lo, 2014, at 3:03 PM, wrote: you and i definitely work on the 'same page' ...A have been emailing him constantly...got this update last night and sent to JE Begin forwarded message: From: Joseph Thakuria ONOMMIEMMMI> Subject: Re: Jeffrey Epstein-Invoice? Date: Janus 9, 2014 5:36:33 PM EST To: , sorry for the delay on my end. On top of work, travel and the holidays,my laptop was out of commission because of problems with the mgh encryption program used to protect patient data for over 1 week which really set me behind on clinical work - as well as this invoice. With some calls over the next few days I should have it wrapped up by Monday. If not, I'll provide quotes on Monday for what I think would be worthwhile pursuing and leave placeholders for anything that still needs follow up on. Joe EFTA_R1_00747110 EFTA02117655 On Thu, Jan 9, 2014 at 7:40 AM, wrote: Hi Joe. Following up with you ... When do you think you might have an invoice ready for Jeffrey? I would love to be able to give him an idea. Thanks so very much Sent from my iPhone On Dec 20, 2013, at 3:01 PM Jose h Thakuria wrote: Hi Sorlealut the delay on this. Things have been more hectic than usual with the holidays and being short-handed in the hospital and I'm still waiting on a few things related to the iPS lines and bioinfonnatics vendors/platforms. I also have some travel planned. Can I get this invoice to you and Jeffrey sometime during the week of 12/30 when things will have started to settle down? Thanks, Joe Thakuria On Thu, Dec 12, 2013 at 4:19 PM wrote: Hi Joe! Thank you so much for this! I have passed along to Jeffrey your findings...lets see what he has to say ... Thanks again, On Dec 12, 2013, at 3:43 PM, Joseph Thakuria e wrote: EFTA_R1_00747111 EFTA02117656 Hi Sony I've been swamped with clinical work. We don't have a fellow this month so I've been in the hospital until late every day this week. Realistically I won't be able to provide a detailed invoice until early next week but here's the general update: 1. I don't think donating sequencing of patient genomes or exomes will be an option anymore. I think it will be too difficult to clear by mgh. And all the patients I had in mind were seen through mgh. Fillet you know if this situation changes. 2. For whole genome sequencing in a clia lab, I think the best bet is to get this done directly through Illumina. The cost for this is $5-10k but I'll run various options by him. They offer just the raw data as well as 2 types of analyses. I think he should do all 3 but I'll include more details in the invoice. (I'm still discussing with people from illumina and waiting for some calls back.) 3. In terms of analysis, since Jeffrey has said cost is not an issue, the best route in my opinion would be to analyze across several of the genomic analyses tools currently available. Though it's not critical to analyze across multiple tools, it's a new enough field that a) they each EFTA_R1_00747112 EFTA02117657 have their own pros/cons, b) I don't think the illumina analyses (both options) provides enough features for in depth analyses (this might seem surprising - but shouldn't be - since they're much more focused on their sequencing instrumentation business over analyses tools), and c) comparing results across the different ones for concordance is worthwhile. I've honed in on 2-4 I think are worth using and will tally up the costs in the invoice. 4. Individualized cell lines: Jeffrey already has fibroblast cell lines from the skin biopsy done for the pgp. Induced pluripotent stem cells (adult stem cells) can be made from these. They can also be induced to differentiate into various cell types including neurons (which would otherwise, of course, be difficult to obtain and study in a specific individual). I'm getting itemized costs but getting to iPS cells costs around SlOk and the process takes about 6 months (because of the multiple cell passages needed in the protocol). (Success of course isn't guaranteed either.) All this work should fall within or just a bit over the $30k or so Jeffrey mentioned over the phone. Payment can be made by your group directly to the various vendors once you have that info. As I discussed with Jeffrey on the EFTA_R1_00747113 EFTA02117658 phone, I won't personally accept money and any effort I contribute to this will be pro bono. And, this goes without saying, but with respect to the vendors, these are just suggestions so Jeffrey should feel free to use other vendors if he has other preferences. I'm happy to go through his genome pro bono using the analyses tools his genomic data from illumina will get loaded onto once it's available. I'm also happy to reassess as well in a year to try and incorporate any new data that may be available relevant to his genome. At that time, there may also be additional data to generate and analyze from studying his iPS or other cell lines. On that front, it may also be interesting to do a genome on his fibroblast cells (which we currently have unlike the iPS cells). I wouldn't expect to get additional medical info from that but it helps give a handle on mutations that are present in the fibros and not him - and later in the iPS cells but not native cells. (And, therefore, give you a handle on how accurately these cells will reflect normal physiology when further studied.) At some point we can compare his white blood cell genome to fibroblast cells to iPS cells and other derived cells. Some of this hassle, such as needing multiple vendors for sequencing and analyses, just EFTA_R1_00747114 EFTA02117659 comes with the territory of being an early adopter. This will get cheaper and the process should be more straightforward over time. And while no one can guarantee benefit from genome sequencing, especially in someone relatively healthy, there is the possibility of reaping benefit as an early adopter before others if something medically actionable is discovered in his data. (We'll also concentrate our analyses on those 56 genes the ACMG recommended checking even in healthy individuals). More to follow and apologies for the delay on the invoice. You can see I've been looking into it though and there are still a few moving pieces. I'm sorry about the news on funding patient sequences. Jeffrey sounded excited about that possibility. His genomic data should be interesting though and even if it's of limited use now, he'll be able to go back and reanalyze the data in the future as more is collectively learned in this field. Best, Joe On Dec 11 2013 5:23 PM, wrote: Hi Joe...can you please give EFTA_R1_00747115 EFTA02117660 me the ETA for Jeffrey's invoice? I'm sorry to keep pestering you, but Jeffrey has asked that I stay on top of this...it is quite important to him. Any update would be tremendously helpful. Ti* you, Assistant to Jeffrey Epstein EFTA_R1_00747116 EFTA02117661